Nkp30 receptor targeted therapeutics
US-2015110760-A1 · Apr 23, 2015 · US
Human alpha-folate receptor chimeric antigen receptor
US12122829B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12122829-B2 |
| Application number | US-202017076359-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 21, 2020 |
| Priority date | Oct 5, 2012 |
| Publication date | Oct 22, 2024 |
| Grant date | Oct 22, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FRα binding domain is fully human, thereby preventing a host immune response.
First claim
Opening claim text (preview).
What is claimed: 1. A chimeric antigen receptor (CAR), wherein the CAR comprises the amino acid sequence of SEQ ID NO: 2. 2. The CAR of claim 1 , further comprising a ligand that specifically binds with CD83. 3. A chimeric antigen receptor (CAR) encoded by the nucleic acid sequence of SEQ ID NO: 13.
Assignees
Inventors
Classifications
Receptors, cell surface antigens or cell surface determinants · CPC title
Chimeric antigen receptors [CAR] · CPC title
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
containing a transmembrane segment · CPC title
containing a signal sequence · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12122829B2 cover?
- The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FRα binding domain is fully human, thereby preventing a host immune response.
- Who is the assignee on this patent?
- Univ Pennsylvania, Fondazione Irccs Istituto Naz Dei Tumori
- What technology area does this patent fall under?
- Primary CPC classification C07K16/28. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).